Key facts
| Price (PPV) | 60.70 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | irbesartanhydrchlorothiazide |
| Class | Agents acting on the renin-angiotensin system |
| ATC code | C09DA04 |
| Manufacturer | PHI |
| Presentation | Boite de 10 |
| Nature | Médicament |
| Hospital price | 37.90 MAD |
| Data collected on | 9/8/2026 |
Indications
Traitement de l'hypertension artérielle essentielle lorsque l'effet d'une monothérapie reste insuffisant. Traitement initial en cas d'hypertension prononcée, lorsqu'un contrôle rapide de la pression artérielle (en termes de jours ou de semaines) est de première importance clinique.
Find an open pharmacy
On-call pharmacies near you
Same-strength alternatives — cheapest first
11 other products contain the same active substance as Irphi Plus 300 mg / 12.5 mg (Irbesartan | Hydrchlorothiazide), at the same strength and in the same dosage form. The prices below are per pack: compare pack sizes before comparing prices.
Same pack size
| Product | Manufacturer | Pack | PPV | Unit price | Difference |
|---|---|---|---|---|---|
| Co-Arapro 300 mg / 12.5 mg | ZENITH PHARMA | Boite de 10 | 60.70 MAD | 6.07 / unit | — |
Other pack sizes
| Product | Manufacturer | Pack | PPV | Unit price |
|---|---|---|---|---|
| Co-Icard 300 mg / 12.5 mg | COOPER PHARMA | Boite de 14 | 85 MAD | 6.07 / unit |
| Co-Irvel 300 mg / 12.5 mg | AFRIC-PHAR | Boite de 14 | 85 MAD | 6.07 / unit |
| Irphi Plus 300 mg / 12.5 mg | PHI | Boite de 20 | 88.50 MAD | 4.43 / unit |
| Co-Irbesar Sun 300 mg / 12.5 mg | SUN PHARMACEUTICALS NORTH AFRICA S.A | Boite de 28 | 158 MAD | 5.64 / unit |
| Co-Irvel 300 mg / 12.5 mg | AFRIC-PHAR | Boite de 28 | 158 MAD | 5.64 / unit |
| Co-Vepran 300 mg / 12.5 mg | SOTHEMA | Boite de 28 | 158 MAD | 5.64 / unit |
| Coavacor 300 mg / 12.5 mg | POLYMEDIC | Boite de 30 | 158.20 MAD | 5.27 / unit |
Substituting a generic is the pharmacist's decision; for medicines listed in schedules A, B and C it still requires a prescription. Public sale prices published by the Directorate of Medicines and Pharmacy, recorded on 9/8/2026.
About Irphi Plus 300 mg / 12.5 mg
Irphi Plus 300 mg / 12.5 mg belongs to the agents acting on the renin-angiotensin system therapeutic class. In Morocco, this drug is marketed by PHI and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Irphi Plus 300 mg / 12.5 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Irphi Plus 300 mg / 12.5 mg
Answers to common questions from Moroccan patients about this drug.